Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
1.01
Oct 20 • 3:59 PM ET Dollar change+0.01 Percentage change(1.00%)
Aftermarket Close
1.06
Aftermarket • 7:09 PM ET Dollar change+0.05 Percentage change(4.95%)
Today, 4:10 PMInovio wins $80.4 million judgment against VGXI and GeneOne, with court awarding compensatory damages and fees and rejecting counterclaims
Index
-
Market Cap
104.43M
Enterprise Value
75.76M
Income
-67.43M
Sales
0.00M
Book/sh
0.05
Cash/sh
0.35
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
112
IPO
Dec 08, 1998
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
19.03
P/C
2.85
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
1.00
Current Ratio
1.00
Debt/Eq
1.83
LT Debt/Eq
1.17
Option/Short
Yes / Yes
EPS (ttm)
-1.18
EPS next Y
-0.43
EPS next Q
-0.20
EPS this Y
57.83%
EPS next Y
44.10%
EPS next 5Y
61.91%
EPS past 3/5Y
49.51% 32.44%
Sales past 3/5Y
-81.47% -61.18%
EPS Y/Y TTM
54.89%
Sales Y/Y TTM
-100.00%
EPS Q/Q
87.83%
Sales Q/Q
-
Insider Own
0.38%
Insider Trans
0.00%
Inst Own
38.84%
Inst Trans
1.49%
ROA
-114.64%
ROE
-409.87%
ROIC
-711.67%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-9.48%
SMA50
-14.06%
SMA200
-21.97%
Trades
Shs Outstand
103.40M
Shs Float
103.01M
52W High
2.72 -62.87%
52W Low
0.56 79.33%
Volatility
9.03% 7.32%
ATR (14)
0.08
RSI (14)
40.10
Beta
1.65
Rel Volume
2.63
Avg Volume
4.05M
Volume
10,644,240
Perf Week
1.18%
Perf Month
-18.55%
Perf Quarter
-4.72%
Perf Half Y
-10.62%
Perf YTD
-41.95%
Perf Year
-59.11%
Perf 3Y
-82.09%
Perf 5Y
-98.80%
Perf 10Y
-99.00%
Prev Close
1.00
Price
1.01
Change %
1.00%
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
CEODr. Jacqueline E. Shea Ph.D.
Chief Financial OfficerMr. Peter D. Kies
M.B.A.Dr. Michael Sumner B.S.
Chief Scientific Officer & Chairman of the Scientific Advisory BoardDr. Laurent M. Humeau Ph.D.
General CounselMr. Robert L. Crotty J.D.